Gilead's Sovaldi, Harvoni Get Exclusive HCV Placement On CVS/Caremark Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
CVS Health’s pharmacy benefit management subsidiary has opted for full coverage of Gilead’s hepatitis C virus drugs over AbbVie’s combination HCV drug Viekira Pak on its commercial formularies for 2015, citing them as the “lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C.”
You may also be interested in...
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
Are Manufacturers Willing To Do Outcomes-Based Pricing? Payers Are Skeptical
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.